NCT06870409View on ClinicalTrials.gov

Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

February 5, 2028

Study Completion Date

February 5, 2029

Conditions
Endocarditis, Bacterial
Interventions
DRUG

Bacteriophage

"Complex drug of 3-4 virulent phages to each type of bacteria, active against:~* Staphylococcus spp. \[Staphylococcus aureus, CoNS (S. epidermidis, S. haemolyticus, S. hominis, S. warneri, S. capitis)\].~* Streptococcus spp. \[Streptococcus viridans (Str. mutans, Str. sanguis, Str. mitis, Str. cristatus, Str. gordonii, Str. oralis, Str. salivarius), Gemella hemolysans, Str. bovis (Str. gallolyticus), Str. constellatus, Str. anginosus, Str. agalactiae\].~* Enterococcus spp. \[E. faecalis, E. faecium\].~* Non-HACEK \[E. coli, A. baumanii, K. pneumoniae, P. aeruginosa\]"

Trial Locations (1)

Unknown

RECRUITING

University Clinical Hospital named after V.V.Vinogradov (branch) of the Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow

All Listed Sponsors
lead

University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)

OTHER